Table 3.
Hazard ratio (95 %CI) for COVID-19 mortality according to tertiles of anti-SARS-CoV-2 specific IgG responses.
| Proteins | Model |
Tertile of proteins [log2(FI)] |
p trend | ||
|---|---|---|---|---|---|
| T1 | T2 | T3 | |||
| N | Model 1 | 1 | 0.63(0.38–1.05) | 0.40(0.22–0.73) | 0.002 |
| Model 2 | 1 | 0.79(0.46–1.34) | 0.73(0.39–1.37) | 0.52 | |
| E | Model 1 | 1 | 1.07(0.59–1.92) | 1.25(0.72–2.20) | 0.41 |
| Model 2 | 1 | 1.11(0.59–2.09) | 1.25(0.68–2.29) | 0.56 | |
| NSP1 | Model 1 | 1 | 3.05(1.38–6.71) | 3.76(1.77–8.03) | 0.0006 |
| Model 2 | 1 | 2.84(1.21–6.63) | 3.10(1.38–6.99) | 0.02 | |
| NSP2 | Model 1 | 1 | 0.96(0.53–1.75) | 1.30(0.75–2.26) | 0.3 |
| Model 2 | 1 | 0.76(0.39–1.45) | 1.18(0.66–2.11) | 0.64 | |
| NSP4 | Model 1 | 1 | 1.90(0.98–3.66) | 2.06(1.09–3.90) | 0.03 |
| Model 2 | 1 | 2.74(1.29–5.85) | 2.60(1.24–5.46) | 0.03 | |
| NSP5 | Model 1 | 1 | 1.08(0.60–1.95) | 1.48(0.85–2.57) | 0.15 |
| Model 2 | 1 | 1.15(0.60–2.22) | 1.79(0.98–3.27) | 0.07 | |
| NSP7 | Model 1 | 1 | 4.43(1.85–10.62) | 4.94(2.10–11.64) | 0.0003 |
| Model 2 | 1 | 4.01(1.52–10.53) | 4.28(1.67–10.98) | 0.008 | |
| NSP8 | Model 1 | 1 | 2.71(1.23–5.98) | 3.91(1.84–8.32) | 0.0002 |
| Model 2 | 1 | 2.34(0.99–5.52) | 3.20(1.42–7.21) | 0.009 | |
| NSP9 | Model 1 | 1 | 1.92(0.92–4.01) | 3.28(1.65–6.54) | 0.0003 |
| Model 2 | 1 | 1.40(0.64–3.07) | 2.69(1.29–5.61) | 0.005 | |
| NSP10 | Model 1 | 1 | 3.55(1.46–8.59) | 5.36(2.28–12.60) | <0.0001 |
| Model 2 | 1 | 3.19(1.22–8.38) | 4.89(1.92–12.46) | 0.0005 | |
| RdRp | Model 1 | 1 | 2.17(1.00–4.69) | 3.57(1.74–7.32) | 0.0002 |
| Model 2 | 1 | 2.31(1.02–5.20) | 2.80(1.30–6.02) | 0.02 | |
| NSP14 | Model 1 | 1 | 1.75(0.79–3.85) | 3.49(1.70–7.14) | 0.0001 |
| Model 2 | 1 | 1.37(0.59–3.19) | 2.65(1.23–5.71) | 0.007 | |
| NSP15 | Model 1 | 1 | 1.03(0.56–1.90) | 1.40(0.80–2.45) | 0.2 |
| Model 2 | 1 | 0.85(0.44–1.65) | 1.23(0.68–2.22) | 0.49 | |
| NSP16 | Model 1 | 1 | 0.91(0.49–1.70) | 1.52(0.87–2.64) | 0.09 |
| Model 2 | 1 | 0.71(0.36–1.39) | 1.40(0.78–2.50) | 0.28 | |
| ORF3a | Model 1 | 1 | 1.03(0.63–1.68) | 0.50(0.27–0.92) | 0.04 |
| Model 2 | 1 | 1.35(0.79–2.29) | 0.69(0.35–1.33) | 0.53 | |
| ORF3b | Model 1 | 1 | 1.63(0.77–3.43) | 3.20(1.66–6.17) | 0.0001 |
| Model 2 | 1 | 1.68(0.76–3.70) | 2.69(1.34–5.38) | 0.02 | |
| ORF7b | Model 1 | 1 | 0.60(0.35–1.03) | 0.45(0.26–0.81) | 0.005 |
| Model 2 | 1 | 0.79(0.45–1.39) | 0.71(0.39–1.30) | 0.2 | |
| ORF9b | Model 1 | 1 | 1.66(0.87–3.15) | 2.02(1.11–3.68) | 0.02 |
| Model 2 | 1 | 1.72(0.86–3.43) | 2.11(1.11–4.04) | 0.03 | |
FI: Fluorescence Intensity, CI: confidence interval, T1: first tertile, T2: second tertile, T3: third tertile. The tertiles cutoffs of IgG responses ([log2(FI)]) against each protein were shown in Supplementary Tables 1. Cox proportional-hazards model was performed to estimate the hazard ratios (HRs) and 95% CIs, and linear trend p-values were calculated by modeling the median value of each antibody tertiles as a continuous variable.
Model 1: Adjusted for age and sex.
Model 2: Additional adjustment for hypertension, diabetes, lymphopenia, increased alanine aminotransferase, and increased lactate dehydrogenase.